Patient ‐reported outcomes for NAFLD/NASH: rational for expanded use
This article is protected by copyright. All rights reserved. (Source: Hepatology)
Source: Hepatology - November 25, 2018 Category: Internal Medicine Authors: Patrizia Carrieri,
Martin Duracinsky,
Fabienne Marcellin,
Jeffrey V Lazarus Tags: Correspondence Source Type: research
Diagnosis and treatment of alcohol use disorder in patients with end ‐stage alcoholic liver disease
This article is protected by copyright. All rights reserved. (Source: Hepatology)
Source: Hepatology - November 24, 2018 Category: Internal Medicine Authors: Fabio Caputo,
Marco Domenicali,
Mauro Bernardi Tags: Concise Review Source Type: research
New strategies for the management of decompensated cirrosis: long ‐term albumin administration for everyone?
This article is protected by copyright. All rights reserved. (Source: Hepatology)
Source: Hepatology - November 23, 2018 Category: Internal Medicine Authors: Elsa Sol à,
Cristina Solé,
Pere Ginès Tags: Hepatology Elsewhere Source Type: research
Sexual dysfunction and sex hormone abnormalities in patients with cirrhosis: Review of pathogenesis and management
This article is protected by copyright. All rights reserved. (Source: Hepatology)
Source: Hepatology - November 23, 2018 Category: Internal Medicine Authors: Shuet Fong Neong,
Emma O. Billington,
Stephen E. Congly Tags: Review Source Type: research
New strategies for the management of decompensated cirrosis: long ‐term albumin administration for everyone?
This article is protected by copyright. All rights reserved. (Source: Hepatology)
Source: Hepatology - November 23, 2018 Category: Internal Medicine Authors: Elsa Sol à,
Cristina Solé,
Pere Ginès Tags: Hepatology Elsewhere Source Type: research
Sexual dysfunction and sex hormone abnormalities in patients with cirrhosis: Review of pathogenesis and management
This article is protected by copyright. All rights reserved. (Source: Hepatology)
Source: Hepatology - November 23, 2018 Category: Internal Medicine Authors: Shuet Fong Neong,
Emma O. Billington,
Stephen E. Congly Tags: Review Source Type: research
Short ‐Duration AL‐335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis
Conclusions: In treatment ‐naïve subjects without cirrhosis, AL‐335 + odalasvir + simeprevir for 6‐8 weeks was generally safe and highly efficacious against HCV GT1. However, inadequate efficacy was observed for the 2‐DAA regimen in GT1‐infected subjects and the 3‐DAA regimen in GT3‐infected subjects. (Source: Hepatology)
Source: Hepatology - November 19, 2018 Category: Internal Medicine Authors: Edward J. Gane,
Catherine A. Stedman,
Christian Schwabe,
Leen Vijgen,
Sushmita Chanda,
Thomas N. Kakuda,
John Fry,
Lawrence M. Blatt,
Matthew W. McClure Tags: Original Article Source Type: research
Bile Microinfarcts in Cholestasis Are Initiated by Rupture of the Apical Hepatocyte Membrane and Cause Shunting of Bile to Sinusoidal Blood
Conclusion: Bile microinfarcts occur in the acute phase after BDL in a limited number of dispersed hepatocytes followed by larger infarcts involving neighboring hepatocytes, and they allow leakage of bile from the BS ‐overloaded biliary tract into blood, thereby protecting the liver from BS toxicity; in the chronic phase after BDL, reduced sinusoidal BS uptake is a dominant protective factor, and the kidney contributes to the elimination of BS until cholemic nephropathy sets in. (Source: Hepatology)
Source: Hepatology - November 19, 2018 Category: Internal Medicine Authors: Ahmed Ghallab,
Ute Hofmann,
Selahaddin Sezgin,
Nachiket Vartak,
Reham Hassan,
Ayham Zaza,
Patricio Godoy,
Kai Markus Schneider,
Georgia Guenther,
Yasser A. Ahmed,
Aya A. Abbas,
Verena Keitel,
Lars Kuepfer,
Steven Dooley,
Frank Lammert,
Chri Tags: Original Article Source Type: research
Short ‐Duration AL‐335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis
Conclusions: In treatment ‐naïve subjects without cirrhosis, AL‐335 + odalasvir + simeprevir for 6‐8 weeks was generally safe and highly efficacious against HCV GT1. However, inadequate efficacy was observed for the 2‐DAA regimen in GT1‐infected subjects and the 3‐DAA regimen in GT3‐infected subjects. (Source: Hepatology)
Source: Hepatology - November 19, 2018 Category: Internal Medicine Authors: Edward J. Gane,
Catherine A. Stedman,
Christian Schwabe,
Leen Vijgen,
Sushmita Chanda,
Thomas N. Kakuda,
John Fry,
Lawrence M. Blatt,
Matthew W. McClure Tags: Original Article Source Type: research
Bile Microinfarcts in Cholestasis Are Initiated by Rupture of the Apical Hepatocyte Membrane and Cause Shunting of Bile to Sinusoidal Blood
Conclusion: Bile microinfarcts occur in the acute phase after BDL in a limited number of dispersed hepatocytes followed by larger infarcts involving neighboring hepatocytes, and they allow leakage of bile from the BS ‐overloaded biliary tract into blood, thereby protecting the liver from BS toxicity; in the chronic phase after BDL, reduced sinusoidal BS uptake is a dominant protective factor, and the kidney contributes to the elimination of BS until cholemic nephropathy sets in. (Source: Hepatology)
Source: Hepatology - November 19, 2018 Category: Internal Medicine Authors: Ahmed Ghallab,
Ute Hofmann,
Selahaddin Sezgin,
Nachiket Vartak,
Reham Hassan,
Ayham Zaza,
Patricio Godoy,
Kai Markus Schneider,
Georgia Guenther,
Yasser A. Ahmed,
Aya A. Abbas,
Verena Keitel,
Lars Kuepfer,
Steven Dooley,
Frank Lammert,
Chri Tags: Original Article Source Type: research
Safety and Efficacy of Ledipasvir –Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6‐11
Conclusion: Ledipasvir –sofosbuvir was well tolerated and highly effective in children 6 to<12 years old with chronic HCV. (Source: Hepatology)
Source: Hepatology - November 17, 2018 Category: Internal Medicine Authors: Karen F. Murray,
William F. Balistreri,
Sanjay Bansal,
Suzanne Whitworth,
Helen M. Evans,
Regino P. Gonzalez ‐Peralta,
Jessica Wen,
Benedetta Massetto,
Kathryn Kersey,
Jiang Shao,
Kimberly L. Garrison,
Bandita Parhy,
Diana M. Brainard,
Rone Tags: Original Article Source Type: research
MicroRNA Sequencing Identifies a Serum MicroRNA Panel, Which Combined With Aspartate Aminotransferase to Platelet Ratio Index Can Detect and Monitor Liver Disease in Pediatric Cystic Fibrosis
Conclusion: We identified a distinct circulatory miRNA profile in pediatric CFLD with potential to accurately discriminate liver disease and fibrosis severity in children with CF. (Source: Hepatology)
Source: Hepatology - November 15, 2018 Category: Internal Medicine Authors: Diego A. Calvopina,
Mark D. Chatfield,
Anna Weis,
Miranda A. Coleman,
Manuel A. Fernandez ‐Rojo,
Charlton Noble,
Louise E. Ramm,
Daniel H. Leung,
Peter J. Lewindon,
Grant A. Ramm Tags: Original Article Source Type: research
